Prof. Stephen Mackinnon, Consultant Haematologist

Prof. Stephen Mackinnon

Consultant Haematologist

Prof. Stephen Mackinnon MB, ChB, MD, FRCPath, MRCP (UK)

Consultant Haematologist

MB, ChB, MD, FRCPath, MRCP (UK)

Prof. Stephen Mackinnon

Consultant Haematologist MB, ChB, MD, FRCPath, MRCP (UK)

MB, ChB, MD, FRCPath, MRCP (UK)

Areas of expertise

  • Leukaemia
  • Lymphoma
  • Myeloma
  • Myelofibrosis

Address

  • UCH Macmillan Cancer Centre

    Bloomsbury, London, WC1E 6AG

About Prof. Stephen Mackinnon

GMC number: 2547514

Year qualified: 1980

Place of primary qualification: University of Glasgow

Areas of expertise

  • Leukaemia
  • Lymphoma
  • Myeloma
  • Myelodysplasia

Professional memberships

Royal College of Physicians
British Society for Haematology
American Society of Haematology
British Society for Blood and Marrow Transplantation
European Society for Blood and Marrow Transplantation
American Society for Blood and Marrow Transplantation

Articles by Prof. Stephen Mackinnon

A reply to hurley et al. regarding recipients receiving better hla-matched hematopoietic cell transplantation grafts, uncovered by a novel hla typing method, have superior survival: a retrospective study

Better hla matching as revealed only by next generation sequencing technology results in superior overall survival post-allogeneic haematopoietic cell transplantation with unrelated donors

Presence of donor-encoded centromeric kir b content increases the risk of infectious mortality in recipients of myeloablative, t-cell deplete, hla-matched hct to treat aml

Recipients receiving better hla-matched hematopoietic cell transplantation grafts, uncovered by a novel hla typing method, have superior survival: a retrospective study

Reducing the diversity of allogeneic transplant protocols in the uk through a bsbmt anthony nolan protocol harmonization initiative

Role of hla-b exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

Predictors of recovery following allogeneic cd34+-selected cell infusion without conditioning to correct poor graft function